AlenCiken

IMV Updates Rapid Progress on COVID-19 Vaccine Program

NASDAQ:IMV   None
IMV Updates Rapid Progress on COVID-19 Vaccine Program

-Received agreement with Health Canada on Phase 1 clinical study design protocol which also includes older patients of 56 years and above

-Completed cGMP formulation and manufacturing process development for clinical trials

-Ready and prepared for Clinical Trial Application submission for regulatory approval

"Next milestones are anticipated as we commence phase 1 clinical trials this summer with results in the Fall of 2020. Once results are published, we plan to initiate phase 2 clinical trials in the second half of the year."

www.imv-inc.com/inve...d-19-vaccine-program

finance.yahoo.com/ne...arket-130158025.html


Declinazione di responsabilità

Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.